The estimated Net Worth of Ismail Kola is at least $107 mil dollars as of 19 November 2021. Ismail Kola owns over 85,000 units of Athersys Inc stock worth over $10,180 and over the last 14 years he sold ATHX stock worth over $0. In addition, he makes $97,300 as Independent Director at Athersys Inc.
Sign up
Ismail Kola ATHX stock SEC Form 4 insiders trading
Ismail has made over 2 trades of the Athersys Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 85,000 units of ATHX stock worth $81,600 on 19 November 2021.
The largest trade he's ever made was buying 85,000 units of Athersys Inc stock on 19 November 2021 worth over $81,600. On average, Ismail trades about 5,263 units every 92 days since 2010. As of 19 November 2021 he still owns at least 100,000 units of Athersys Inc stock.
You can see the complete history of Ismail Kola stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ismail Kola biography
Dr. Ismail Kola serves as Independent Director of the Company. Dr. Kola has served as a Director since October 2010. In retirement, Dr. Kola is a Senior Partner at Forepont Capital, a pharmaceutical venture capital company since April 2019. He was Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and President of UCB New Medicines, UCB’s discovery research through to proof-of-concept in man organization, from November 2009 until his retirement in December 2017. Dr. Kola was formerly Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine at Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, a pharmaceutical company, and Chief Scientific Officer at Schering-Plough Corporation, from March 2007 until his appointment at UCB. Prior to Schering-Plough, Dr. Kola held senior positions from January 2003 to March 2007 at Merck, a pharmaceutical company, where he was Senior Vice President and Site Head, Basic Research. From 2000 to 2003, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, at Pharmacia Corporation, a pharmaceutical company. Prior to his position with Pharmacia, Dr. Kola spent 15 years as Professor of Human Molecular Genetics and was Director of the Centre for Functional Genomics and Human Disease at Monash Medical School in Australia. Dr. Kola received his Ph.D. in Medicine from the University of Cape Town, South Africa, his B.Sc. from the University of South Africa, and his B.Pharm. from Rhodes University, South Africa. Dr. Kola served on the board of directors of Biotie Therapies, Inc. (NASDAQ: BITI) (and previously Synosia, who merged with Biotie) from February 2011 until May 2016 when it was sold to Acorda Therapeutics, where he also served on the compensation committee.
What is the salary of Ismail Kola?
As the Independent Director of Athersys Inc, the total compensation of Ismail Kola at Athersys Inc is $97,300. There are 9 executives at Athersys Inc getting paid more, with Gil Van Bokkelen having the highest compensation of $1,596,650.
How old is Ismail Kola?
Ismail Kola is 63, he's been the Independent Director of Athersys Inc since 2010. There are 3 older and 11 younger executives at Athersys Inc. The oldest executive at Athersys Inc is Lorin Randall, 76, who is the Independent Director.
Insiders trading at Athersys Inc
Over the last 17 years, insiders at Athersys Inc have traded over $3,715,462 worth of Athersys Inc stock and bought 2,242,389 units worth $3,620,264 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Michael B Sheffery, eJordan Davis. On average, Athersys Inc executives and independent directors trade stock every 43 days with the average trade being worth of $3,231. The most recent stock trade was executed by Daniel A. Camardo on 22 November 2022, trading 100,000 units of ATHX stock currently worth $55,000.
What does Athersys Inc do?
athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.
What does Athersys Inc's logo look like?
Complete history of Ismail Kola stock trades at Athersys Inc
Athersys Inc executives and stock owners
Athersys Inc executives and other stock owners filed with the SEC include:
-
Gil Van Bokkelen,
Chairman of the Board, Chief Executive Officer -
John Harrington,
Executive Vice President, Chief Scientific Officer, Director -
William Lehmann,
President, Chief Operating Officer -
Laura Campbell,
Senior Vice President - Finance -
Ivor Macleod CPA, M.B.A.,
Chief Financial Officer & Principal Accounting Officer -
Dr. John J. Harrington,
Co-Founder, Chief Scientific Officer, Exec. VP & Director -
William B. J. Lehmann Jr., M.B.A., J.D., MBA,
Pres, COO, Sec. & Interim CEO -
Lorin Randall,
Independent Director -
Jack Wyszomierski,
Independent Director -
Ismail Kola,
Independent Director -
Jane Wasman,
Director -
Baiju Shah,
Director -
Katherine Kalin,
Director -
Hardy Kagimoto,
Director -
Maia Hansen,
Senior Vice President - Operations, Supply Chain -
Ivor Macleod,
Chief Financial Officer -
Dr. Eric Jenkins M.D.,
Sr. Medical Director & Head of Clinical Operations -
Maia Hansen M.B.A., M.S.,
Sr. VP and Head of Operations & Supply Chain -
Rakesh Ramachandran,
Head of Information Technology & Communications and VP -
Dr. Robert Mays Ph.D.,
VP of Regenerative Medicine & Head of Neuroscience Programs -
Dr. Manal Morsy M.D., PH.D.,
Sr. VP & Head of Global Regulatory Affairs -
Alison O'Sullivan M.B.A.,
Sr. Director of HR -
Karen Hunady M.S.,
Director of Corp. Communications & Investor Relations -
Jordan Davis,
Director -
Lee Babiss,
Director -
Neema Mayhugh,
Director -
Joseph Patrick Nolan,
Director -
K.K. Healios,
-
Tadahisa Kagimoto,
Director -
Robert J Deans,
Sr. Vice President -
Kenneth Traub,
Director -
Advisors Llc Orbi Med Capit...,
-
George M Jr Milne,
Director -
Floyd D Md Loop,
Director -
Advisors Llcisaly Samuel D ...,
-
Michael B Sheffery,
Director -
William C Mulligan,
Director -
Daniel A. Camardo,
CEO